Form 4: Arcutis Director Sells 10,000 Shares Under 10b5-1 Plan

Arcutis Biotherapeutics Director Howard G. Welgus sold 10,000 shares of common stock for approximately $28.96 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Howard G. Welgus, a Director of Arcutis Biotherapeutics, Inc. (ARQT), disposed of 10,000 shares of common stock.
• The transaction occurred on January 2, 2026, at a weighted average sale price of $28.9606 per share.
• The shares were sold in multiple transactions with prices ranging from $28.905 to $29.17, inclusive.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Welgus on March 11, 2025.
• Following the reported transaction, Mr. Welgus directly beneficially owns 69,744 shares of Arcutis Biotherapeutics common stock.
• The 10b5-1 trading plan has an end date of May 29, 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a pre-scheduled sale under a 10b5-1 plan, which is typically for personal financial planning and not indicative of a change in company outlook or performance.

Negatives

• A director reduced their direct beneficial ownership by 10,000 shares, though this was part of a pre-arranged trading plan, which typically mitigates the negative signal of insider selling.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook, as it pertains solely to an insider transaction.

Industry Context

This Form 4 filing reports a routine insider transaction under a pre-arranged trading plan and does not provide broader industry context or competitive analysis.

Stakeholder Impact

• Shareholders: The sale by a director slightly reduces insider ownership, but its impact is mitigated by being a pre-arranged 10b5-1 plan, suggesting it's not based on new material non-public information.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Insider Transaction, Form 4, Stock Sale, 10b5-1 Plan, Director, Equity Disposal